Bill > HB1112

This bill aims to improve access to medication-assisted treatment for opioid use disorder by prohibiting utilization review entities from imposing prior authorization requirements. Specifically, the bill defines "medication for opioid use disorder" as FDA-approved medications prescribed to treat opioid use disorder before January 1, 2025, and defines "utilization review entities" as organizations that manage prior authorization for health benefits, including employers, health plans, and preferred provider organizations. The bill mandates that these entities cannot require prior authorization for medications used to treat opioid use disorder, which could help patients more quickly access potentially life-saving treatments. Both the definitions and the prohibition are set to be in effect from July 1, 2025, and will automatically expire on July 1, 2027, suggesting this is a temporary measure designed to address current challenges in accessing opioid use disorder medications. The bill's provisions are intended to reduce administrative barriers that might prevent individuals from receiving timely treatment for opioid use disorder.

Business and Industry

https://iga.in.gov/legislative/2025/bills/house/1112/details